In a study conducted by Gleeson et al, alterations in MEN1 chromatin remodeling genes and mammalian target of rapamycin (mTOR) pathway genes were found to be the most frequent molecular events identified in pancreatic NET, but it remains unclear whether these biomarkers and other less frequently observed alterations possess predictive value [24]. The gene discussed is MEN1; the disease is pancreatic neuroendocrine tumor.